Allena Pharmaceuticals, Inc.

OTCPK:ALNA.Q Stock Report

Market Cap: US$109.9k

Allena Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Allena Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth24.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Seeking Alpha • Jul 19

First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment

Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday said it had completed enrollment in the first two cohorts of its phase 2a study of its enzyme ALLN-346 in gout patients with stage 2 and stage 3 chronic kidney disease (CKD). ALNA is planning to enroll up to four cohorts in the mid-stage trial, called Study 202, with each cohort consisting of up to 12 patients. Cohort A of the trial has enrolled seven patients with stage 2, or mild CKD, and cohort B has enrolled 12 patients with stage 3, or moderate CKD. ALNA said safety and efficacy data from the first two cohorts of the study are expected to be available later this quarter. ALNA stock +1.5% to $0.15 in morning trading.
Seeking Alpha • Jul 05

Allena Pharma reschedules special meeting to approve reverse stock split, shares fall

Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday said it had rescheduled its special meeting to consider and approve a reverse stock split of its common shares. ALNA stock has lost 16.5% to $0.18 in morning trading. The special meeting had been scheduled for today. ALNA did not give any reasons for the rescheduling decision. According to Seeking Alpha data, ALNA had 114.53M shares outstanding.
Seeking Alpha • Jan 08

Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days

Allena Pharmaceuticals is trading below 10% of analyst price targets. Analysts have not adjusted these price targets down, despite their presence at the January 4 webinar or conference call. Allena Pharmaceuticals must identify a partner, secure a buyout, or arrange for financing in the next 90 days or they will not survive. They, also, face NASDAQ de-listing in February 2022, if they cannot get the price-per-share of their stock above $1 and sustain this price-per-share. I like these “beaten up” stocks for a “nibble” – there really is no bad news left and I cannot believe that they will not get a deal done in the first quarter of 2022. I recommend a very small purchase of Allena Pharmaceuticals stock at or below $0.60 per share in anticipation of a buyout, partnering or financing in the next 90 days.
Analysis Article • Dec 29

Should You Review Recent Insider Transactions At Allena Pharmaceuticals, Inc. (NASDAQ:ALNA)?

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Allena Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:ALNA.Q - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2022N/A-43-49-49N/A
3/31/2022N/A-49-56-56N/A
12/31/2021N/A-49-46-46N/A
9/30/2021N/A-49-42-41N/A
6/30/2021N/A-44-35-34N/A
3/31/2021N/A-37-31-30N/A
12/31/2020N/A-33-29-28N/A
9/30/2020N/A-34-32-32N/A
6/30/2020N/A-39-36-36N/A
3/31/2020N/A-44-42-42N/A
12/31/2019N/A-47-44-44N/A
9/30/2019N/A-46-41-40N/A
6/30/2019N/A-42-40-40N/A
3/31/2019N/A-39-35-35N/A
12/31/2018N/A-36-32-32N/A
9/30/2018N/A-33-30-30N/A
6/30/2018N/A-28-25-25N/A
3/31/2018N/A-24-22-22N/A
12/31/2017N/A-22-21-21N/A
9/30/2017N/A-21-20-20N/A
6/30/2017N/A-23-24-24N/A
3/31/2017N/A-24-25-24N/A
12/31/2016N/A-25-23-23N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALNA.Q's forecast earnings growth is above the savings rate (2.1%).

Earnings vs Market: Insufficient data to determine if ALNA.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ALNA.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ALNA.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ALNA.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALNA.Q's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/30 07:02
End of Day Share Price 2023/05/30 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Allena Pharmaceuticals, Inc. is covered by 10 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Madhu KumarB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.